Alkermes plc buy melinda
Start price
19.06.17
/
50%
€57.15
Target price
05.07.17
€60.00
Performance (%)
5.28%
End price
05.07.17
€60.17
Summary
This prediction ended on 05.07.17 with a price of €60.17. The BUY prediction by melinda finished with a performance of 5.28%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alkermes plc | -2.439% | -2.439% | -22.078% | -3.942% |
| iShares Core DAX® | -1.104% | -6.084% | 0.866% | 54.489% |
| iShares Nasdaq 100 | 0.328% | 2.327% | 18.263% | 85.552% |
| iShares Nikkei 225® | -1.082% | -7.987% | 26.339% | 55.407% |
| iShares S&P 500 | -0.055% | 0.880% | 13.287% | 62.988% |
Comments by melinda for this prediction
In the thread Alkermes plc diskutieren
Die US Food and Drug Administration (FDA) genehmigt hat ALKERMES des zweimonatigen Aristada (Aripiprazol lauroxil) extended-release injizierbare Suspension zur Behandlung von Schizophrenie.